AGC Biologics Expands Capabilities at North America Campus

Adds viral vector suspension technology and capacity for the development and manufacturing of gene therapies.

Author Image

By: Charlie Sternberg

Associate Editor

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA.   These new capabilities, which begin coming online in the third quarter of 2022, complement the campus’ adherent viral vector and cell therapy offerings – enabling AGC Biologics to provide an in-depth variety of end-to-end cel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters